Principal Financial Group
DYN icon

Principal Financial Group’s Dyne Therapeutics DYN Stock Holding History

Principal Financial Group’s Portfolio DYN Stock Details DYN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-7,497
Closed -$269K – 2221
2024
Q3 		$269K Sell
7,497
-6,274
-46% -$250K ﹤0.01% 2047
2024
Q2 		$486K Sell
13,771
-1,632
-11% -$47.4K ﹤0.01% 1963
2024
Q1 		$437K Buy
15,403
+857
+6% +$19.4K ﹤0.01% 2018
2023
Q4 		$193K Sell
14,546
-683
-4% -$6.67K ﹤0.01% 2176
2023
Q3 		$136K Buy
15,229
+1,476
+11% +$15.9K ﹤0.01% 2223
2023
Q2 		$155K Buy
13,753
+2,134
+18% +$25.2K ﹤0.01% 2219
2023
Q1 		$134K Buy
11,619
+950
+9% +$12.3K ﹤0.01% 2247
2022
Q4 		$124K Buy
+10,669
New +$123K ﹤0.01% 2268

Other funds holding DYN

AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Principal Financial Group's DYN Position: Q4 2024 in Review

Principal Financial Group sold out of Dyne Therapeutics (DYN) in Q4 2024, closing a stake of 7,497 shares — an estimated $269K sold.

Principal Financial Group first reported a position in DYN in Q4 2022 and held it in 8 quarters. The position peaked at $486K in Q2 2024. 200 funds tracked by Wall St. Rank hold DYN as of Q4 2024.

  • Principal Financial Group reported no remaining Dyne Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Principal Financial Group sold 7,497 Dyne Therapeutics shares in Q4 2024, an estimated $269K.
  • Principal Financial Group first reported a position in Dyne Therapeutics in Q4 2022 and held it in 8 quarters.
  • Principal Financial Group's Dyne Therapeutics position peaked at $486K in Q2 2024.
  • 200 funds tracked by Wall St. Rank held Dyne Therapeutics as of Q4 2024.

Based on Principal Financial Group's 13F filing for Q4 2024, filed 31 Jan 2025.